UCB PHARMA AS
Score · fiscal year 2025
46of 100
How to read this: the company is ahead of 43 % of companies in the Morning class Medium in the same sector in 2025. What does this mean?
Rank in the Morning class Medium: 2,113 of 3,712 · What are Morning company classes?
Place in the whole sector: 13,269 of 23,059 · Handel
Profile
Beaver · Builder
Lower profitability, lower solidity
Position against comparable companies in 2025, not a verdict on the company. Based on profitability 42 and solidity 39 out of 100 among companies in the Morning class Medium in the same sector in 2025. Methodology
Against the sector
UCB PHARMA AS is 4 points below the median for companies in the Morning class Medium in the same sector in 2025.
Median score 50 among 3,712 companies.
Against companies in the Morning class Medium in the same sector in 2025: operating margin 3.3% (median 3.0%) and equity ratio 24.8% (median 30.0%).
The numbers behind the score
| Measure | Company | Median |
|---|---|---|
| Operating revenue | 263 MNOK | 93 MNOK |
| Operating margin | 3.3% | 3.0% |
| Profit margin | 1.9% | 2.8% |
| Return on assets | 6.0% | 11.6% |
| Equity ratio | 24.8% | 30.0% |
| Debt-to-equity | 3.04 | 2.24 |
| Current ratio | 1.33 | 1.39 |
| Revenue growth | 5.9% | 6.1% |
| Revenue per employee | 52.68 MNOK | 5.07 MNOK |
The median and “ahead of” refer to companies in the Morning class Medium in the same sector in 2025. The bar shows the share of companies the figure is ahead of.
With an index of 46, UCB PHARMA AS does better than 43% of companies in the Morning class Medium in the same sector (3,712 companies) in 2025.
Score 2023–2025
- UCB PHARMA AS
- Median: companies in the Morning class Medium in the same sector
UCB PHARMA AS has a score of 46 for 2025, rank 13,269 of 23,059 in the sector.
Strongest: Consistency: percentile 67 against peers.
Weakest: Solidity: percentile 39 against peers, equity ratio 24.8% against a median of 30.0%.
Worth a closer look
- What lies behind weak solidity, and will it last?
Written by fixed rules from the figures. Describes the figures, does not explain causes. Not investment or financial advice. How the summary is made
What the numbers say
UCB PHARMA AS had an operating margin of 3.3% and an equity ratio of 24.8% in 2025, and ranks 13,269 of 23,059 in Handel.
No large changes in the key figures from 2024 to 2025.
This text is generated automatically from the 2025 accounts.
Three simple methods
The methods give between 40 MNOK and 79 MNOK.
| Method | Multiple | Estimate |
|---|---|---|
| P/E | 10.0 | 40 MNOK |
| EV/EBIT | 8.0 | 79 MNOK |
| P/B | 1.0 | 41 MNOK |
A mechanical estimate from public accounts, not advice. Mechanical estimate from public accounts with fixed multiples. Not a valuation and not advice to buy or sell. The multiples are provisional default values and must be adjusted per sector before the figures are used for anything. See the calculation
Worth a closer look
No rules were triggered for this year.
Indications based on the latest annual accounts from open data. Not investment or financial advice.
Financial costs were 4.0% of the debt in 2025. The policy rate averaged 4.30 % the same year. This is a plain description of what the debt cost, not a model of interest sensitivity.
See interest rates, prices and exchange rates for the sector
Data quality
No anomalies found in the figures.
Scenario analysis: the sector's weakest year
We have no accounts for 2022, the sector's weakest year, for this company.
The sector's weakest year was 2022, with a median operating margin of 1.5%. Based on the 11 fiscal years we have. The analysis grows as more years are fetched or imported. Methodology
What the score is made of
| Profitability | 42 | weight 30% |
|---|---|---|
| Solidity | 39 | weight 25% |
| Liquidity | 45 | weight 15% |
| Growth | 49 | weight 15% |
| Consistency | 67 | weight 15% |
Durability: 47 (average over 3 years)
Index version 2. Data completeness 100%: the share of the weights that had data.
Questions and answers
How profitable is UCB PHARMA AS?
The operating margin was 3.3% in 2025, against a median of 3.0% among companies in the Morning class Medium in the same sector. Return on assets was 6.0%.
How solid is UCB PHARMA AS?
The equity ratio was 24.8% in 2025 (median 30.0%). Debt-to-equity was 3.04 (median 2.24).
What is the liquidity of UCB PHARMA AS like?
The current ratio was 1.33 in 2025 (median 1.39).
How does UCB PHARMA AS compare in Handel?
UCB PHARMA AS ranks 13,269 of 23,059 in Handel for 2025. Among companies in the Morning class Medium it is number 2,113 of 3,712. Revenue changed by 5.9% from the year before.
From the Central Coordinating Register
- Org. no.
- 976281918
- Legal form
- AS
- Sector
- Handel (46.460)
- Morning company class
- Medium
- Employees
- 5 registered 12 May 2025
- Founded
- 20 March 1996 30 years in operation
- Share capital
- 0.49 MNOK
- Business address
- Haakon VIIs gate 6, 0161 OSLO
- Municipality
- Oslo rank 63–220 of 357 in Norway
- Latest accounts filed
- 2025
Source: Central Coordinating Register, Brønnøysund Register Centre. The employee count is reported by the company and may be older than the accounts. See the company at the Brønnøysund Register Centre
Ownership and roles
- Chief executive
- Fredrik Arneberg
- Chair of the board
- Christina Dyreborg Jeppesen
- Board member
- Jaana Mattila
- Board member
- Fredrik Arneberg
- Auditor
- FORVIS MAZARS AS
- Accountant
- KPMG ACCOUNTING AS
- Accountant
- AZETS INSIGHT AS
Source: Central Coordinating Register, fetched 29 October 2026. Only names are shown.
Owners and shareholdings will appear here once the shareholder data extract is in place.
Coming · not built yet
Error in the data?
Do you see an error in the figures or in how the company is mapped (sector, holding, group)? Let us know. Corrections require documentation.
Figures last fetched 28 October 2026.
Year by year · 2023–2025
| Key figure | 2023 | 2024 | 2025 | Trend |
|---|---|---|---|---|
| Index | 41 | 52 | 46 | |
| Rank | 13,278 | 10,547 | 13,269 | |
| Operating margin | 3.3% | 3.4% | 3.3% | |
| Return on assets | 6.2% | 7.1% | 6.0% | |
| Equity ratio | 22.3% | 28.7% | 24.8% | |
| Current ratio | 1.28 | 1.40 | 1.33 | |
| Revenue growth | – | 9.3% | 5.9% |
Accounts
From the Brønnøysund Register Centre, in the company's reporting currency (NOK).
| Key figure | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating revenue | 227.5 MNOK | 248.6 MNOK | 263.4 MNOK |
| Operating profit | 7.5 MNOK | 8.5 MNOK | 8.7 MNOK |
| Profit before tax | 5.9 MNOK | 5.4 MNOK | 5.1 MNOK |
| Net profit | 4.4 MNOK | 3.6 MNOK | 4.0 MNOK |
| Financial expenses | 3.2 MNOK | 4.0 MNOK | 5.0 MNOK |
| Total assets | 148.8 MNOK | 132.8 MNOK | 167.3 MNOK |
| Current assets | 148.6 MNOK | 132.7 MNOK | 167.3 MNOK |
| Equity | 33.1 MNOK | 38.1 MNOK | 41.4 MNOK |
| Retained earnings | 27.9 MNOK | 31.6 MNOK | 35.5 MNOK |
| Total liabilities | 115.6 MNOK | 94.7 MNOK | 125.9 MNOK |
| Current liabilities | 115.6 MNOK | 94.7 MNOK | 125.9 MNOK |
Source: Brønnøysund Register Centre (Register of Company Accounts), fetched 28 October 2026, accounts id 6747772.
Further
Similar companies
- BARKONSULT AS index 46, rank 13,255 · compare
- FOODTECH INTERIØR OG STORKJØKKEN AS index 46, rank 13,257 · compare
- SPESIALGROSSISTEN MATFYLKET AS index 46, rank 13,261 · compare
- KARL STORZ ENDOSKOPI NORGE AS index 46, rank 13,282 · compare
- KM DAGLIGVAREHANDEL AS index 46, rank 13,285 · compare